Literature DB >> 34252408

Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts.

Cheng-Che Lee1, Wei-Ting Chen2, Syue-Yi Chen2, Tsung-Ming Lee3.   

Abstract

We have demonstrated that dapagliflozin, a sodium-glucose cotransporter (SGLT) 2 inhibitor, attenuates reactive oxygen species (ROS) production. Connexin43 playing a role in ventricular arrhythmia is sensitive to redox status. No data are available on the effects of dapagliflozin on arrhythmogenesis. This study was to determine whether dapagliflozin attenuated arrhythmias through modulating AMP-activated protein kinase (AMPK)/free radicals-induced connexin43 after myocardial infarction. After coronary ligation, normoglycemic male Wistar rats were randomized to either vehicle or dapagliflozin (0.1 mg/kg per day) for 4 weeks. Myocardial ROS levels were significantly increased (p < 0.05) and connexin43 levels were substantially decreased after myocardial infarction (p < 0.05). Dapagliflozin administration was associated with increased SGLT1, attenuated ROS and increased connexin43 levels in myocardium (all p < 0.05). During programmed electrical stimulation, arrhythmic severity was significantly improved in the dapagliflozin-treated infarcted rats than those in the vehicle-treated infarcted rats (p < 0.05). Dapagliflozin significantly increased AMPK phosphorylation compared to vehicle after infarction (p < 0.05). Inhibition of AMPK signaling by SBI-0206965 prevented increased SGLT1 and blocked the effects of dapagliflozin on attenuated ROS levels and increased connexin43 phosphorylation (all p < 0.05). SGLT1 inhibited by KGA-2727 showed attenuated ROS levels and increased connexin43 phosphorylation (both p < 0.05) although AMPK phosphorylation was not changed, implying SGLT1 activation was mediated by AMPK in dapagliflozin-treated hearts. Dapagliflozin-treated hearts had significantly increased connexin43 phosphorylation (p < 0.05), which was significantly decreased after adding 3-morpholinosydnonimine (p < 0.05). These data indicate that clinically-relevant dapagliflozin concentrations decreased free radicals content and increased connexin43 levels through AMPK-dependent and SGLT1-independent mechanisms, which attenuated ventricular arrhythmias in the normoglycemic infarcted rats.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmia; Connexin43; Dapagliflozin; Free radicals; Myocardial infarction

Year:  2021        PMID: 34252408     DOI: 10.1016/j.bcp.2021.114674

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus.

Authors:  Po-Jui Chi; Chung-Jen Lee; Yi-Jen Hsieh; Chia-Wen Lu; Bang-Gee Hsu
Journal:  Int J Med Sci       Date:  2022-04-04       Impact factor: 3.642

2.  Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Ziwei Yin; Huizhen Zheng; Zhihua Guo
Journal:  Front Cardiovasc Med       Date:  2022-05-18

Review 3.  Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress.

Authors:  Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

4.  Exercise-Generated β-Aminoisobutyric Acid (BAIBA) Reduces Cardiomyocyte Metabolic Stress and Apoptosis Caused by Mitochondrial Dysfunction Through the miR-208b/AMPK Pathway.

Authors:  Yanan Yu; Wewei Chen; Ming Yu; Jinsha Liu; Huan Sun; Ping Yang
Journal:  Front Cardiovasc Med       Date:  2022-02-25

5.  Sodium-glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway.

Authors:  Xiaoping Zhan; Lijun Cheng; Ning Huo; Lin Yu; Changle Liu; Tong Liu; Guangping Li; Huaying Fu
Journal:  Front Cardiovasc Med       Date:  2022-09-06

6.  Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.

Authors:  Jinchun Wu; Tao Liu; Shaobo Shi; Zhixing Fan; Roddy Hiram; Feng Xiong; Bo Cui; Xiaoling Su; Rong Chang; Wei Zhang; Min Yan; Yanhong Tang; He Huang; Gang Wu; Congxin Huang
Journal:  Cardiovasc Diabetol       Date:  2022-09-28       Impact factor: 8.949

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.